Niagen Bioscience Inc (NAGE) Common Stock USD0.001

Sell:$7.54Buy:$7.63$0.15 (2.02%)

Prices delayed by at least 15 minutes
Sell:$7.54
Buy:$7.63
Change:$0.15 (2.02%)
Prices delayed by at least 15 minutes
Sell:$7.54
Buy:$7.63
Change:$0.15 (2.02%)
Prices delayed by at least 15 minutes

Company Information

About this company

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Key people

Robert N. Fried
Chief Executive Officer, Director
Ozan Pamir
Chief Financial Officer
Carlos Luis Lopez
Senior Vice President, General Counsel
Frank L. Jaksch
Chairman of the Board
Steven D. Rubin
Lead Independent Director
Ann Cohen
Independent Director
Gary Ng
Independent Director
Kristin Patrick
Independent Director
Click to see more

Key facts

  • Shares in issue
    79.75m
  • EPIC
    NAGE
  • ISIN
    US1710774076
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $592.56m
  • Employees
    104
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.